Maryam Sadat Sadati

Maryam Sadat Sadati

Auto-generated profile, based on publicly available information

Maryam Sadat Sadati

Dermatology Department, Shiraz University of Medical Sciences, Shiraz, Iran

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2014 in Dermatology Research and Practice
Verified
Journal Article
Open access
PDF file
LDLadan Dastgheib
Ladan Dastgheib
ZMZohreh Mostafavi-Pour
Zohreh Mostafavi-Pour
AAAhmad Adnan Abdorazagh
Ahmad Adnan Abdorazagh
ZKZahra Khoshdel
Zahra Khoshdel
MSMaryam Sadat Sadati
Maryam Sadat Sadati
MGMahsa Ghavipisheh
Mahsa Ghavipisheh
Background. Alopecia areata (AA) is an autoimmune condition, in which hair is lost from some areas of the body. Though its etiopathogenesis is not fully understood, there are claims that imbalance of trace elements may trigger the onset of AA, by distorting immune functions. In this study, we tried to investigate the relationship between AA and iron, zinc, and copper levels of serum and hair.Materials and Methods. Sixteen female patients with AA (14–40 years old) and 27 healthy female controls were enrolled in this study. Serum and hair level of iron, zinc, and copper were measured by flame emission spectroscopy. The resulting data was analyzed with SPSS15.Results. We did not detect a significant difference in the serum and hair level of iron, zinc, and copper between patients and controls. There was a significant correlation between serum and hair level of iron (r=0.504, P=0.001), zinc (r=0.684, P=0.0001), and copper (r=0.759,P=0.0001) in patients and controls.Discussion and Conclusion. According to this study, there was no statistically significant difference between trace elements among AA patients and controls. So the trace elements level in hair and serum may not be relevant to the immunologic dysfunction that exists in AA patients.

27 August 2013 in Journal of Dermatological Treatment
Verified
Journal Article
Closed access
PDF file
FHFarhad Handjani
Farhad Handjani
EBEbrahim Behazin
Ebrahim Behazin
MSMaryam Sadat Sadati
Maryam Sadat Sadati
Introduction: Molluscum contagiosum (MC) is a common cutaneous viral infection. Potassium hydroxide (KOH), as a strong alkali, and cryotherapy have been used for its treatment. The objective of this study was to compare these two treatment modalities. Methods: 30 patients, aged between 1 and 24 years of age, were randomly divided into 2 groups: 15 were treated with KOH 10% solution and 15 were treated with cryotherapy. KOH 10 % was applied by the patient or their parent(s) two times a day until the lesions disappeared completely. Cryotherapy was performed with liquid nitrogen spray, repeated weekly for 4 weeks. The assessment of response and side effects were performed weekly for 4 weeks. Results: In the KOH group, 86.6% had complete response, 6.7% had partial response and 6.7% had no response after 4 weeks. In the cryotherapy group, 93.3% had complete response and 6.7% had partial response. There was no statistically significant difference between the two groups (p > 0.05). Postinflammatory hyperpigmentation, as a side effect, was mostly noted with cryotherapy. Conclusion: Both treatment modalities were equally effective. Since KOH is inexpensive and confers better cosmetic results compared to cryotherapy, it can be used as a suitable treatment modality for MC.

20 February 2014 in Journal of Dermatological Treatment
Verified
Journal Article
Closed access
LDLadan Dastgheib
Ladan Dastgheib
MSMaryam Sadat Sadati
Maryam Sadat Sadati
MBMohammad Baghernejhad
Mohammad Baghernejhad
Introduction: To investigate the therapeutic efficacy of tacrolimus compared with azathioprine in the treatment of pemphigus vulgaris. About 23 patients received prednisolone and azathioprine, and 23 patients prednisolone and tacrolimus for 6 months. Pemphigus activity scores, the time that new bulla formation stopped, the time corticosteroid was tapered, cumulative steroid dosage and medication side effects were analyzed. In the control group, the new bulla formation was ceased after a mean ± SD of 11.8 ± 4.7 days, and steroid tapering was done after a mean ± SD of 28.3 ± 5.45 days. Of the 23 patients receiving prednisolone and tacrolimus, the new bulla formation was ceased after a mean ± SD of 12.9 ± 5.26 days, and steroid tapering was done after a mean ± SD of 28.2 ± 5.39 days. About 8.6% of patients did not reach remission in each group. In patients receiving azathioprine, life-threatening side effects were seen in 1 (4.7%), moderate side effects in 2 (9.5%) and mild side effects in 1 (4.7%). In patients receiving tacrolimus, moderate side effect was seen in 1 (5%) and mild in 1 (5%). Tacrolimus effects are comparable to azathioprine as pemphigus vulgaris adjuvant treatment, also it has less severe side effects. Trial registration No. IRCT2012073010450N1 available at www.IRCT.ir.

31 January 2024 in Dermatology Practical & Conceptual
Verified
Journal Article
Open access
PDF file
MZMaryam Zarrabi
Maryam Zarrabi
NGNasser Gholijani
Nasser Gholijani
ZAZahra Amirghofran
Zahra Amirghofran
MSMaryam Sadat Sadati
Maryam Sadat Sadati
RRRoya Radanfar
Roya Radanfar
Citation: Zarrabi M, Gholijani N, Amirghofran Z, Sadati MS, Radanfar R. Evaluation of IL-38, a Newly-Introduced Cytokine, in Sera of Vitiligo Patients and its Relation to Clinical Features. Dermatol Pract Concept. 2024;14(1):e2024027. DOI: https://doi.org/10.5826/dpc.1401a27 Accepted: July 24, 2023; Published: January 2024 Copyright: ©2024 Zarrabi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (BY-NC-4.0), https://creativecommons.org/licenses/by-nc/4.0/, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited. Funding: None. Competing interests: None. Authorship: All authors have contributed significantly to this publication. Corresponding author: Maryam Sadat Sadati. Department of dermatology, Shiraz University of Medical Sciences, Shiraz, Iran. E-mail: msadati63@yahoo.com Introduction: Vitiligo is thought to be an autoimmune disorder caused by melanocytes dysfunction and depigmentation. Among different executors of the immune system in developing the disease, the role of various cytokines has been defined. Objectives: We have focused on IL-38, the tenth member of IL-1 cytokine family with a proposed anti-inflammatory role, which has not hitherto been introduced as an anti-inflammatory factor in vitiligo. Methods: Sixty-nine generalized vitiligo patients and 72-year-old- and sex-matched healthy individuals were included in this study. IL-38 level was evaluated in sera of all participants using ELISA assay. The relation of IL-38 level to patients characteristics was evaluated. Results: IL-38 serum level in vitiligo patients (159.5±39.7 pg/ml) was lower than the healthy controls (166.7±34.8pg/ml) (P = 0.039). A weak negative correlation between the age of male patients and their IL-38 serum levels was identified (r = 0.38, P = 0.058). Evaluation of the IL-38 serum levels relationship with patients clinical characteristics showed no correlation with disease onset, stage of depigmentation, and disease activity status. Conclusions: The lower levels of IL-38 as an anti-inflammatory cytokine support the inflammatory nature of vitiligo. It indicates the difference of IL-38 in sera of vitiligo patients and healthy controls, as the first report of the lower level of this cytokine in the context of vitiligo. The reason of this difference remains to be clarified; as there are not sufficient study reports revealing the role of gender, ethnicity and inflammation on the cytokine network in the context of vitiligo. Keywords : vitiligo, interleukin38, cytokine, skin This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

7 November 2022 in Journal of Cosmetic Dermatology
Verified
Journal Article
Open access
MSMaryam Sadat Sadati
Maryam Sadat Sadati
RRRoya Radanfar
Roya Radanfar

31 January 2024 in Dermatology Practical & Conceptual
Verified
Journal Article
Open access
PDF file
MGMehdi Ghahartars
Mehdi Ghahartars
Hossein HosseiniHossein Hosseini
Hossein Hosseini
MKMalek Khedri
Malek Khedri
MSMaryam Sadat Sadati
Maryam Sadat Sadati
Introduction: Pityriasis versicolor (PV) often exhibits recurrence even despite treatment, and a standardized therapy with a complete cure rate remains elusive. Given the fungicidal property of amphotericin B, its potential for PV treatment warrants investigation. Objectives: This study aimed to compare the efficacy of topical liposomal amphotericin B and clotrimazole cream in treating PV. Methods: A randomized controlled trial was conducted with 44 PV patients, aged 15 to 70 years, who were equally assigned to either the amphotericin or clotrimazole group. The trial was registered at the Iranian Registry of Clinical Trials on March 7th, 2022. PV diagnosis was confirmed in all patients through positive microscopic results. The amphotericin group received topical gel containing liposomal amphotericin B 0.4%, while the other group received topical cream containing clotrimazole 1%. Both treatments were applied twice daily to the affected skin lesions for 14 days. The primary outcomes assessed were mycologic cure, clinical cure, and complete cure at day 14 post-treatment. Results: Both drugs demonstrated successful treatment outcomes, with comparable rates of mycologic cure (77.3%), clinical cure (63.6%), and complete combined cure (63.6%). There was no significant difference between the groups in terms of the degree of cure (P=0.75). Adjustments for age, sex, lesion extent, and lesion site yielded insignificant risk ratio and risk difference estimates for the complete cure rate (P>0.05). Conclusions: The topical application of liposomal amphotericin B 0.4% is equally effective as topical clotrimazole 1% in treating pityriasis versicolor. These findings suggest that liposomal amphotericin B could be considered as a viable alternative treatment for PV. Further research is warranted to explore its long-term consequences and safety profile.